Kraig Biocraft Laboratories, Inc. (OTC: KBLB)

Kraig Biocraft Laboratories, Inc. develops high strength fibers using recombinant DNA technology for commercial applications including technical textiles. The company employs genetically engineered silkworms that produce spider silk proteins to create recombinant spider silk fiber. Its products target performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and other markets requiring high strength and lightweight materials. By combining spider silk proteins with native silkworm proteins, the firm creates unique recombinant silk fibers that aim to surpass existing materials in strength, resilience and flexibility. The technology relies on the silkworm’s natural silk glands, which devote about 40% of the caterpillar’s weight to producing fibroin, an insoluble protein spun into silk threads. Kraig’s scientists insert spider silk genes into silkworm embryos using plasmid DNA and state of the art molecular biology techniques, resulting in transgenic silkworms that express the desired silk proteins. This work began in collaboration with the University of Notre Dame and was later moved to the company’s own research and development headquarters after support from the U. S. Army.

The company generates revenue primarily through the sale of its recombinant spider silk fibers and related products to customers in the targeted application areas. It also expects to earn income from licensing its genetic engineering technology and from collaborative development agreements with manufacturers. Revenue is derived from supplying fibers for use in performance textiles, protective gear, medical devices and other industrial applications. As of the filing date, Kraig Biocraft Laboratories, Inc. has not yet reported significant product sales and remains in a pre revenue phase focused on scaling production and advancing its technology. The firm anticipates that future revenue will grow as it secures supply agreements with textile manufacturers and expands its footprint in the specialty fiber and technical textile markets.

Kraig Biocraft Laboratories, Inc. positions itself as a leader in the emerging recombinant spider silk industry, claiming to be the world’s foremost developer of commercially scalable and cost effective spider silk fiber. Its main competitors include Bolt Threads, Inc. based in California, Spiber Inc. based in Japan and AMSilk based in Germany. The company asserts that its production method, which uses domesticated silkworms, offers lower costs and a smaller environmental footprint compared with the synthetic processes used by rivals. While the sector remains fragmented with no dominant player, Kraig believes its proprietary gene splicing technology and integrated sericulture approach give it a competitive edge. The global market for technical textiles was estimated at greater than $200 billion in 2024 and is projected to reach $272 billion by 2030, according to industry sources cited in the filing. Kraig believes its recombinant spider silk fiber can address demand for high performance materials in sectors such as ballistic protection, aerospace composites and medical implants due to its combination of strength, toughness and light weight. The firm also highlights the biodegradable and biocompatible nature of its silk based products as an additional advantage over petroleum derived synthetic fibers.

The company serves manufacturers and brands across sectors such as performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants and cosmetics. It reports receiving unsolicited requests from leading businesses in these markets for material samples and development collaborations. Although specific customer names are not disclosed in the filing, the described customer base consists of textile producers, garment makers, medical device manufacturers and industrial parts suppliers seeking high strength, light weight fibers. Kraig has indicated that it is engaged in discussions with companies involved in protective equipment, automotive components and industrial filtration to evaluate the suitability of its silk fibers for end use applications. The firm’s strategy involves working under non disclosure agreements to secure collaborative development arrangements and to establish limited channel exclusivity with partners that share its innovation focus.